secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0001193125-26-017226
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt
--------------------------------------------------------------------------------

- Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.
- Three additional tranches up to $75M available upon achieving clinical, regulatory, and commercial milestones; final $25M at Hercules' discretion.
- Maturity date January 1, 2030; proceeds support detalimogene BLA filing in H2 2026 and potential launch in 2027.
- Non-dilutive capital strengthens balance sheet for planned BLA in BCG-unresponsive NMIBC with carcinoma in situ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/0001193125-26-017226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/engn-20260120.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-017226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer